We are delighted to announce that Professor Claudia Mauri will join Clinical & Experimental Immunology (CEI) as Editor-in-Chief from January 2025 for a four-year term. Professor Mauri, a globally renowned immunologist, succeeds Professor Leonie Taams, who held the role of Editor-in-Chief of CEI from 2016-2024.
Professor Mauri brings a wealth of expertise to CEI, with a research focus on the role of regulatory B cells in autoimmune diseases such as lupus and rheumatoid arthritis, as well as in cancer. She was Professor of Immunology at the Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London, since 2002 and recently moved to the Infection and Immunity Division at the Pears Building Institute of Immunity and Transplantation.
“I am honoured to have been selected for the position of Editor-in-Chief of CEI,” said Professor Mauri. “The journal has long published high-quality research in translational immunology, and I look forward to collaborating with the editorial board and authors to feature research that has the potential to transform clinical practice and improve patient outcomes. Professor Taams has done an outstanding job of heading up the journal over the past eight years, and I look forward to building on her success by raising the profile of CEI, and establishing the journal as the place to go to publish work at the intersection of translational and clinical immunology.”
Since 1966, CEI has been amongst the foremost journals in the field of translational and clinical immunology, publishing research articles that have the potential to transform our understanding of the immunopathology of human disease and inform updates to clinical practice.
Articles in the journal apply ideas, insights and discoveries generated through scientific studies to the treatment, prevention or diagnosis of human disease. Additionally, articles with a clinical immunology focus encompass the application of state-of-the-art technologies such as next-generation sequencing, metagenomics and high-dimensional phenotyping to understand the mechanisms that govern the outcomes of clinical trials.
“This position also allows me to support the British Society for Immunology (BSI), which plays a vital role in empowering immunologists in the UK,” continued Professor Mauri. “As a not-for-profit publisher, the BSI reinvests all revenue from its journals into the immunology community through grants, events, and training opportunities. I am thrilled to contribute to this mission and embrace this exciting new challenge.”
With Professor Mauri’s leadership, CEI is poised to advance its reputation as a trusted source for groundbreaking immunology research that bridges the gap between science and medicine. The BSI’s publishing portfolio, which includes Clinical & Experimental Immunology, Immunotherapy Advances, and Discovery Immunology, exemplifies its commitment to advancing the field and championing immunologists and their work.